<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0005">
 <label>Table 1</label>
 <caption>
  <p>Potential therapeutic agents as repurposed drugs for the treatment of COVID-19.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug (Year of first usage)</th>
    <th>Class &amp; Type</th>
    <th>Rationale for Use</th>
    <th>Target Disease</th>
    <th>Dosage in Current Trials</th>
    <th>Supportive Evidence</th>
    <th>Caveats</th>
    <th>References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <bold>Remdesivir</bold>(2014)
    </td>
    <td>Antiviral; Adenosine nucleotide analogue</td>
    <td>Acts as an RNA-chain terminator by binding to RNA dependent RNA polymerase (RdRP).</td>
    <td>Ebola</td>
    <td>200 mg intravenously (IV) on day 1 followed by 100 mg IV daily for up to 10 days (NCT04292899)</td>
    <td>Effective against SARS and MERS in-vitro</td>
    <td>Not currently FDA-approved. Can only be obtained via compassionate use.</td>
    <td>
     <xref rid="b0170" ref-type="bibr">[34]</xref>, 
     <xref rid="b0175" ref-type="bibr">[35]</xref>, 
     <xref rid="b0180" ref-type="bibr">[36]</xref>, 
     <xref rid="b0185" ref-type="bibr">[37]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Lopinavir/Ritonavir (LPV/r)</bold>(2000)
    </td>
    <td>Antiviral; Protease inhibitors</td>
    <td>HIV type 1 aspartate protease inhibitor with inhibitory activity against SARS-CoV in-vitro.</td>
    <td>HIV</td>
    <td>400/100 mg twice daily for 14 days. (NCT04321174)</td>
    <td>Effective against SARS-CoV-1 both in vitro and human studies</td>
    <td>Current data suggest a limited role in treatment of COVID-19.</td>
    <td>
     <xref rid="b0225" ref-type="bibr">[45]</xref>, 
     <xref rid="b0230" ref-type="bibr">[46]</xref>, 
     <xref rid="b0235" ref-type="bibr">[47]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Oseltamivir</bold>(1999)
    </td>
    <td>Antiviral; Neuraminidase inhibitor</td>
    <td>Inhibits viral replication.</td>
    <td>Influenza</td>
    <td>75 mg orally twice a day for 5 days (NCT04338698)</td>
    <td>No in-vitro activity against SARS-CoV</td>
    <td>Has no role in the management of COVID-19 once influenza has been ruled out. No data against SARS.</td>
    <td>
     <xref rid="b0250" ref-type="bibr">[50]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Favipiravir</bold>(2014)
    </td>
    <td>Antiviral; RNA polymerase inhibitor</td>
    <td>RNA-dependent RNA polymerase inhibitor. Also involved in blocking viral replication.</td>
    <td>Influenza, arenavirus, filovirus</td>
    <td>1600 mg twice daily on day 1, then 600 mg twice daily thereafter for 7 days (NCT04310228)</td>
    <td>In vitro activity seen against SARS-CoV-2</td>
    <td>No available data on its efficacy and safety for the treatment of COVID-19</td>
    <td>
     <xref rid="b0170" ref-type="bibr">[34]</xref>, 
     <xref rid="b0260" ref-type="bibr">[52]</xref>, 
     <xref rid="b0265" ref-type="bibr">[53]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Ribavirin</bold> (1986)
    </td>
    <td>Antiviral; Nucleoside analogue</td>
    <td>Inhibits viral RNA synthesis and mRNA capping.</td>
    <td>Syncytial virus, viral hemorrhagic fever,</td>
    <td>400 mg twice daily for 14 days (NCT04276688)</td>
    <td>No evidence in SARS and MERS</td>
    <td>Risks of ADR (hematologic toxicity, teratogenicity &amp; contraindications in pregnancy) outweigh potential clinical benefit.</td>
    <td>
     <xref rid="b0170" ref-type="bibr">[34]</xref>, 
     <xref rid="b0250" ref-type="bibr">[50]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Camostatmesylate</bold> (2006)
    </td>
    <td>Protease inhibitors</td>
    <td>Blocks viral maturation and entry to cells. Inhibits TMPRSS2.</td>
    <td>Pancreatitis</td>
    <td>2 × 100 mg pills 3 times daily for 5 days (NCT04321096)</td>
    <td>Effectively blocked SARS-CoV-2 in lung cells in vitro. Also showed antiviral activity in an animal model for SARS-CoV infection</td>
    <td>Limited data available.</td>
    <td>
     <xref rid="b0285" ref-type="bibr">[57]</xref>, 
     <xref rid="b0290" ref-type="bibr">[58]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Hydroxychloroquine / chloroquine</bold> (HCQ/CQ) (1955/1934)
    </td>
    <td>Antimalarial</td>
    <td>Block viral entry into cells by inhibiting glycosylation of host receptors, proteolytic processing, and endosomal acidification.</td>
    <td>Malaria</td>
    <td>Chloroquine: 500 mg twice daily for 10 days
     <break/>Hydroxychloroquine: 400 mg twice daily × 1 day then 200 mg twice daily × 5 days (NCT04345692)
    </td>
    <td>In vitro activity against SARS-CoV-2</td>
    <td>Paucity of adequate data to validate their use in COVID-19.Concerns of cardiac arrhythmias</td>
    <td>
     <xref rid="b0260" ref-type="bibr">[52]</xref>, 
     <xref rid="b0295" ref-type="bibr">[59]</xref>, 
     <xref rid="b0305" ref-type="bibr">[61]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Tocilizumab</bold> (2005)
    </td>
    <td>Monoclonal Antibody</td>
    <td>IL-6 inhibitor. May block cytokine storm in COVID-19 patients.</td>
    <td>Rheumatoid arthritis</td>
    <td>8 mg/kg IV (up to a maximum of 800 mg per dose), with an interval of 12 h(NCT04317092)</td>
    <td>No data on SARS or MERS.</td>
    <td>Limited data to support current use.</td>
    <td>
     <xref rid="b0335" ref-type="bibr">[67]</xref>
    </td>
   </tr>
   <tr>
    <td>
     <bold>Methylpred-nisolone</bold> (1957)
    </td>
    <td>Corticosteroids</td>
    <td>Potent anti-inflammatory and antifibrotic properties; May prevent “cytokine storm”; reduce pulmonary and systemic inflammation in pneumonia.</td>
    <td>Arthritis, psoriasis, etc.</td>
    <td>120 mg/day IV infusion for 3 days (NCT04345445)</td>
    <td>No impact on clinical outcomes in SARS</td>
    <td>No proven benefit for their use in COVID-19. Risks of ADRs outweigh the benefits</td>
    <td>
     <xref rid="b0365" ref-type="bibr">[73]</xref>, 
     <xref rid="b0370" ref-type="bibr">[74]</xref>
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>This table represents a list of repurposed therapeutic agents that are being used for the treatment of COVID-19, their class, mechanism of action, dosage, original target disease, and evidence supporting their use in COVID-19 patients.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
